Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GSK Investigates 'Different Pricing Options' Following CHMP Nod For 'Bubble Boy' Gene Therapy

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline PLC's 'bubble boy' treatment has been given a positive opinion by the European Medicines Agency's advisory committee.


Related Content

VC Roundup: Magenta Raises $48.5m To Improve Stem Cell Transplants